Sabina Lee

Contributor in
Industry Trends Emerging Technologies

Sabina Lee is a senior consultant for W Medical Strategy Group, a healthcare consulting firm that uses deep industry expertise to help a wide range of global healthcare companies achieve their mission. She has more than two decades of leading communications strategy and business development in academia, startups and government. An editorial board member for the World Asian Medical Journal (WAMJ) since 2019, she served as editor-in-chief for the New York Health Forum magazine.

Industry Trends | Emerging Technologies | Biotech Companies

tags: AI in Drug Discovery AI in Healthcare Biotech Research Drug Discovery and Development Startups

Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.

Posts by this author

How Syntekabio’s Supercomputing Enables AI-driven Drug Discovery

What is "supercomputing"? It refers to processing a massive quantity of complex data-intensive and computation-heavy problems often found in scientific or engineering projects. Using a powerful class of ‘multiple’ computer systems working in parallel, supercomputing is built into an infrastructure that is supporting a vast array of disciplines. From quantum mechanics and molecular modeling to weather forecasting and exploration of oil and gas, it has brought about massive waves of transformations to some of the key industries today.

The Power of STB CLOUD in Remote AI Drug Discovery

STB CLOUD is Syntekabio’s latest cloud-based, fully automated AI platform. It’s designed for developers to engage in their drug discovery and development processes to find drug candidates easier and faster.

The State of A.I. Drug Discovery and Its Future: Small Molecules, Vaccines, and Antibodies

Artificial intelligence (A.I.) and big data in a synergistic integration have led to promising results in new drug development by drastically reducing cost and time. This trend in the biopharmaceutical market has emerged as a new industry standard as startups—each with distinctive core A.I. algorithm—fiercely compete to capture their global market share. Syntekabio, the first KOSDAQ-listed A.I. driven biotech company in South Korea, shares its view on the current and future trajectory of A.I. drug discovery and development in a series of exclusive articles for BiopharmaTrend.

Democratizing Early Drug Discovery through Artificial Intelligence: Interview with Syntekabio CEO Jongsun Jung

Before the age of modern drug discovery, the pharmaceutical industry had been plagued with uncertainty and processing challenges, including the timescales, length, complexity and cost of drug discovery. So, what is transforming the biopharma industry and the future of our humanity? The answer lies in two words: artificial intelligence (AI).

Once an obscure concept when the term was coined in 1956, AI has become ubiquitous in 2023. It’s been widely adopted to perceive, synthesize and infer information, retool processes, and restructure products. From Alexa to facial recognition, AI and machine learning are part of everyday life from here to Timbuktu. It is also central to driving three major factors most critical for companies: the ability to cut expenses, develop faster, and grow efficiently in less time.